Print

AVEG 028

A Phase I Safety and Immunogenicity Trial of Orally Administered Recombinant Salmonella Typhi CVD 908 delta asd (pW57-asd+) Expressing HIV-1 LAI gp120 (VVG 203) and Parenterally Administered HIV-1 MN rgp120 in Alum in HIV-1 Uninfected Volunteers

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) December 05, 1997
Salmonella typhi CVD 908-HIV-1 LAI gp 120 ,MN rgp120 Bacterium Env gp120 B MN; Protein Env gp120 B MN
Salmonella typhi CVD 908-HIV-1 LAI gp 120 Bacterium + gp 120
MN rgp120 Protein
USA 47
NCT00000868
http://www.clinicaltrials.gov/ct2/show/NCT00000868